Publicaciones en las que colabora con Ascensión López Díaz de Cerio (12)

2019

  1. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

    Nature Medicine, Vol. 25, Núm. 3, pp. 470-476

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  2. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

2017

  1. Targeting NK-cell checkpoints for cancer immunotherapy

    Current Opinion in Immunology, Vol. 45, pp. 73-81

2008

  1. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis

    European Journal of Immunology, Vol. 38, Núm. 2, pp. 576-586

2007

  1. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions

    Journal of Investigative Dermatology, Vol. 127, Núm. 7, pp. 1673-1680

2006

  1. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

    Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301

2004

  1. Inmunoterapia activa en el tratamiento de neoplasias hematológicas

    Anales del sistema sanitario de Navarra, Vol. 27, Núm. 1, pp. 45-62

  2. Past, present and future of anti-idiotype vaccination

    Revista de medicina de la Universidad de Navarra, Vol. 48, Núm. 3, pp. 14-23

2003

  1. CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

    Journal of Immunology, Vol. 171, Núm. 11, pp. 5931-5939

  2. Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies

    Clinical Cancer Research, Vol. 9, Núm. 15, pp. 5454-5464

2001

  1. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity

    European Journal of Immunology, Vol. 31, Núm. 6, pp. 1780-1789